CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation on Monday, April 29, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 in Vancouver, Canada. “We are pleased to have more data confirming the ability of our oral plasma kallikrei